Better Therapeutics Aktie Logo
US08773T1043
A3CY5N
BTTX

Better Therapeutics Aktie

Forecast

Buy
  2
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Better Therapeutics Aktie had revenue of €0 and net profit of -€37.07m

(EUR) 2022
YoY
Revenue 0 -
Gross profit -2.54m 78.69%
Net profit -37.07m 4.50%
EBITDA -33.13m 2.62%

Fundamentals

Metric Value
Market capitalization
€4.97k
Number of shares
54.52m
52-week high/low
€0.000182 - €0.0000911
Dividends No
Beta
0.18
P/E ratio
0.00
PEG ratio
0.00
P/B ratio
0.00
P/S ratio
0.00

Company profile

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Name
Better Therapeutics Aktie
CEO
Craig R. Jalbert
Headquarters San Francisco, ca
USA
Website
Sector
Health Care
Industry
Health Care Providers & Services
IPO
17/03/2021
Employees 54

Ticker symbols

Exchange Symbol
NASDAQ
BTTX
🍪

Parqet  uses cookies. Learn more